All In MedTech

FDA Clearance Tracker · P150025-S018

PD-L1 IHC 28-8 pharmDx

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jul 1, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jul 1, 2026

Approved

Time to decision

180 days

Received Jan 2, 2026. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P150025-S018
Device name
PD-L1 IHC 28-8 pharmDx
Applicant location
Santa Clara, CA
Received
Jan 2, 2026
Decided
Jul 1, 2026
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P150025

Device type

Device class
Class III

Every decision under product code PLS

FDA's approval statement

As written in FDA's record.

Approval for the PD-L1 IHC 28-8 pharmDx for expanding the indications to include use as an aid in identifying patients with esophageal squamous cell carcinoma (ESCC), and gastric, gastroesophageal junction (GEJ) and esophageal adenocarcinoma for treatment with OPDIVO (nivolumab) or OPDIVO QVANTIG (nivolumab and hyaluronidase-nvhy).

Source documents

Other decisions for Agilent Technologies, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.